Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Parker Institute for Cancer Immunotherapy

Founders Leo Nissola Sean Parker

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$79M
Portfolio companies 6
Rounds per year 1.29
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Genetics
  • Manufacturing
Summary

Parker Institute for Cancer Immunotherapy appeared to be the Corporate Investor, which was created in 2016. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the San Francisco.

Among the most popular portfolio startups of the fund, we may highlight ArsenalBio, ImaginAb. The fund has no specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Health Care, Biotechnology.

The current fund was established by Sean Parker.

The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Parker Institute for Cancer Immunotherapy, startups are often financed by Penn Medicine Co-Investment Fund, Novartis Venture Fund, Lilly Asia Ventures. The meaningful sponsors for the fund in investment in the same round are Ping An Ventures, Penn Medicine Co-Investment Fund, Lilly Asia Ventures. In the next rounds fund is usually obtained by Penn Medicine Co-Investment Fund, Lilly Asia Ventures, Gilead Sciences.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Parker Institute for Cancer Immunotherapy:
Typical Co-investors
Parker Institute for Cancer Immunotherapy is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Parker Institute for Cancer Immunotherapy:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alphamundi Switzerland, Zürich, Zurich
Bailihong Chuangtou China, Guangdong, Shenzhen
Calpoly Ventures -
Chuangrong Capital Beijing, China, Shijingshan
Cox Automotive Atlanta, Georgia, United States
EnerDel New York, New York, United States
First Rays Venture Partners California, San Francisco, United States
Frontier International Japan, Tokyo
Horatio Ventures NYC -
Ideamed Health Group Bavaria, Bayern, Germany
Innovum Invest Helsingborg, Skane Lan, Sweden
J.E. Berman Associates -
Madhu Kela Family Office -
MAF Mauritius -
MedAngels -
Montrose Capital Partners New York, New York, United States
OpenDoor Venture Capital New York, New York, United States
RACSeedSpark -
Vestigo Ventures Cambridge, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Psioxus Therapeutics

Biotechnology
Health Care
Therapeutics
$30M05 Jan 2023 Vale of White Horse, England, United Kingdom

ArsenalBio

Artificial Intelligence
Biotechnology
Cloud Computing
$220M06 Sep 2022 South San Francisco, California, United States

Senti Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$50M09 Jun 2022 South San Francisco, California, United States

Affini-T Therapeutics

Biotechnology
Health Care
Therapeutics
$175M22 Mar 2022 Watertown, Massachusetts, United States

ArsenalBio

Artificial Intelligence
Biotechnology
Cloud Computing
$85M17 Oct 2019 South San Francisco, California, United States

Tmunity Therapeutics

Biotechnology
Genetics
Health Care
Manufacturing
Therapeutics
$35M19 Apr 2018 Philadelphia, Pennsylvania, United States

Tmunity Therapeutics

Biotechnology
Genetics
Health Care
Manufacturing
Therapeutics
$100M23 Jan 2018 Philadelphia, Pennsylvania, United States

ImaginAb

Biotechnology
Clinical Trials
Health Care
Health Diagnostics
$8M14 Sep 2017 Inglewood, California, United States

Tmunity Therapeutics

Biotechnology
Genetics
Health Care
Manufacturing
Therapeutics
$10M09 Dec 2015 Philadelphia, Pennsylvania, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Parker Institute for Cancer Immunotherapy?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: